WARF Ventures

Hubble Therapeutics is a biotechnology company focused on developing gene therapies for inherited retinal diseases, including Leber congenital amaurosis type 16. It is pursuing a proprietary gene therapy platform to treat this rare disorder, aiming to reverse vision loss and restore sight with a single treatment.

Madison Scientific develops an integrated management solution for hydrocephalus patients. Their core product is a novel implantable medical device that monitors and regulates cerebrospinal fluid drainage in real-time. This device integrates an intracranial pressure sensor, communication modules, and a valve system to optimize fluid flow, reducing shunt failure rates and improving patient outcomes.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Quiver Quantitative is a platform designed to democratize access to alternative data for retail investors. It aggregates unique datasets typically reserved for institutions, such as credit card transaction history and social media data, and presents them in a user-friendly web dashboard.

Transfur is a referral management platform focused on enhancing the efficiency of animal medical record handling. The platform utilizes artificial intelligence to extract, analyze, and present clinically relevant data from veterinary records. This technology aids pet specialists in the seamless requesting, sending, managing, and reviewing of medical records, ultimately reducing the time spent on non-billable activities. By streamlining the referral management process, Transfur aims to improve the overall workflow for veterinary professionals and enhance the care provided to animals.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.